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Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with several
modifiable (sedentary life-style, smoking, malnutrition, hypoxemia) and non-modifiable
(age, co-morbidities, severity of pulmonary function, respiratory infections) risk factors. We
hypothesise that most of these risk factors may have a converging and deleterious effects
on both respiratory and peripheral muscle function in COPD patients.
Methods: Amulticentre study was carried out in 121 COPD patients (92%males, 63 11 yr, FEV1,
49  17%pred). Assessments included anthropometrics, lung function, body composition using
bioelectrical impedance analysis (BIA), and globalmuscle function (peripheralmuscle (dominant
and non-dominant hand grip strength, HGS), inspiratory (PImax), and expiratory (PEmax) muscle
strength). GOLD stage, clinical status (stable vs. non-stable) and both current and past hospital
admissions due to COPD exacerbations were included as covariates in the analyses.
Results: Respiratory and peripheral muscle weakness were observed in all subsets of patients.
Muscle weakness, was significantly associated with both current and past hospitalisations.
Patients with history of multiple admissions showed increased global muscle weakness afterde Pneumologia, Hospital del Mar, Passeig Marı´tim 25-29, E-08003 Barcelona, Spain. Tel.: þ34
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Muscle dysfunction and risk of exacerbation in COPD 1897adjusting by FEV1 (PEmax, ORZ 6.8, p < 0.01; PImax, ORZ 2.9, p < 0.05; HGSd, ORZ 2.4, and
HGSnd, ORZ 2.6, pZ 0.05). Moreover, a significant increase in both respiratory and peripheral
muscle weakness, after adjusting by FEV1, was associated with current acute exacerbations.
Conclusions: Muscle dysfunction, adjusted by GOLD stage, is associated with an increased risk of
hospital admissions due to acute episodes of exacerbation of the disease. Current exacerbations
further deteriorate muscle dysfunction
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a relevant
health problem in most developed countries due to its high
prevalence and enormous costs, both direct and indirect,
which generate a tremendous burden on healthcare
systems.1 In Spain, COPD affects about 9% of the adult
population (40e70 years old) and is the fourth largest cause
of hospital admission and death in this age group.1,2
The natural history of COPD implies a series of respira-
tory symptoms and periods of clinical exacerbation that
decrease not only the quality of life but also life expec-
tancy.3 Exacerbation is clinically defined by worsened
dyspnoea, worsened sputum volume and/or change in its
colour, and new or worsened cough.2 There is limited
information describing the clinicalephysiological changes
in patients admitted to hospital with an exacerbation of
COPD. Although several groups of authors have studied the
risk factors of exacerbation in relation to hospital read-
mission for COPD patients, no study has specifically focused
on muscle dysfunction.
One of the frequent extrapulmonary manifestations of
COPD is skeletal muscle dysfunction and wasting.4 With
increasing severity of disease, patients with COPD loose
muscle bulk, especially in their thighs and upper arms. Over
time, exercise endurance decreases in these patients and
they complain of dyspnoea and leg discomfort with mild to
moderate workload increases.5 These symptoms curtail
exercise capacity and compromise cardiac fitness, which
further limits exercise tolerance, creating a vicious down-
ward spiral that can eventually lead to generalised debility
and immobility.6 Skeletal muscle dysfunction contributes to
reduce health status of patients with COPD and substan-
tially increases the risk of mortality, independent of
traditional markers of COPD mortality such as baseline lung
function, age, and cigarette smoking.7,8 Encouragingly,
early interventions with exercise programmes may restore
some of the lost health status related to muscle dysfunction
and increase patients’ exercise tolerance and stamina.9
It is clearly recognised that, whereas one group of COPD
patients may rarely need hospital admission during exac-
erbations, other groups of patients are prone to multiple
admissions.2 There are a few of studies suggesting that
inspiratory and expiratory muscle dysfunction could act as
a modifiable risk factor of hospital admission in patients
with COPD. Martı´nez-Llorens et al.10 using a case-control
study design showed that exacerbations of COPD associates
with pronounced deleterious changes in skeletal muscle
function in association with acute loss of muscle mass. In
other setting, Gonza´lez et al.11 clearly identified that
respiratory muscle overload (defined as a high pressure-
time index of the inspiratory muscles) as a risk factor ofhospital readmission in a 1-year follow-up of a cohort of
patients with moderate-to-severe COPD. We hypothesised
that patients with higher risk for severe exacerbations have
a limited ventilatory reserve and that respiratory muscle
dysfunction underlies and negatively affects the balance
between functional reserve and acute loading imposed by
exacerbation.12 We thus considered that (1) a greater
respiratory muscle dysfunction can be present even at the
stable clinical conditions in patients with greater risk for
hospital admission, and (2) that global muscle involvement
could be captured by measuring inspiratory, expiratory and
peripheral muscle strength. To test these hypotheses,
a multicentre study was performed in two subsets of COPD
patients defined by their clinical stability (present or
absent). In a post-hoc analysis, the history of hospital
admissions (none, current, or multiple hospitalisations) was
taken in account in the analyses.
Methods
This was a multicentre, cross-sectional study carried out
over two consecutive years. The principles of the Declara-
tion of Helsinki13 were applied and all patients gave written
informed consent to participate. The study was approved
by the Ethics Committees at all the centres participating in
the study.
Candidates were all patients with COPD assigned to two
cohorts: 1) patients admitted to the hospital due to exac-
erbations of COPD, and 2) stable COPD patients that
currently go to the hospital for their regular follow-up.
Those subsets of patients were defined by their clinical
stability (present or absent). In a post-hoc analysis, the
history of hospital admissions (none, current, or multiple
hospitalisations) was taken into account for the definition
of study groups. Group 1 was composed of patients who
attended regular hospital follow-up but had never required
hospital admission. Group 2 included clinically stable COPD
patients defined as three or more months from the last
exacerbation with a history of multiple (three or more)
hospital admissions during the last year. Group 3 was
composed of patients admitted to hospital for the very first
time with a physician diagnosis of an acute exacerbation of
COPD. Finally, Group 4 included patients with acute
exacerbation but admitted to the hospital on multiple
(three or more) occasions. Only patients requiring level II
admission that is hospitalisation in a medical ward but not
in the ICU14 were included in the study. In the latter two
groups (3 and 4), a respiratory physiotherapist performed
an early (<48 hours of admission) assessment that included:
1) body weight; 2) inspiratory and expiratory muscle
strength (expressed as maximal expiratory and inspiratory
mouth pressures, respectively); 3) peripheral muscle
1898 J. Vilaro´ et al.strength (measured by hand dynamometry) and 4) body
composition (bioelectrical impedance analysis, expressed
in both absolute and relative values). Conventional blood
and biochemical analyses were also taken for all patients
and all prescribed drugs were systematically recorded.
Exclusion criteria were as follows: pneumonia, infection
from any other organ, left heart failure, previous myocar-
dial infarction, previous or present pulmonary embolism,
asthma or the need for ventilatory support. In addition,
patients were excluded if they had chronic respiratory
failure and relevant comorbidity. These were defined as the
presence or suspicion of recent orthopaedic, medical, or
surgical diseases that could affect muscle structure and
function and introduce confusion factors into the analysis.
Peripheral oedema, suspicion of ascites, hormonal therapy
for causes other than hyperglycaemia associated with
steroid therapy during admission, and history of chronic
systemic steroid therapy were considered additional
exclusion criteria Current smoking was not considered an
exclusion criterion.
Measurements
Body weight (in kilograms) was assessed using officially
approved floor scales (SECA, Berlin, Germany). Patients
were weighed in light clothing, barefoot and with an empty
bladder. Values were rounded to nearest 100 g. Height (in
m) was measured using a wall-mounted stadiometer. Body
mass index (BMI) was calculated with the formula weight/
height2 (kg/m2). To assess body compartments, bioelec-
trical impedance analysis (BIA) was performed using
portable equipment (BODYSTAT 1500, Bodystat LTD, Isle
of Man, British Isles). Fat, muscle mass and total body water
were determined and expressed as relative values to total
body weight. Arterial blood was taken following conven-
tional techniques. Gas analyses were performed (Beckman
Coulter, Synchron Cx9Po, Germany). Forced spirometry
(Sibel, Barcelona, Spain), static lung volumes, airway
resistance, and carbon monoxide diffusing capacity (Mas-
terlab, Jaeger, Wu¨rzburg, Germany) were assessed in all
patients.15e17 Inspiratory and expiratory muscle strength
were assessed by determining maximal respiratory mouth
pressures during voluntary manoeuvres. Patients were
instructed to carry out maximal respiratory efforts with
occluded airway.18 Maximal inspiratory pressure (PImax) was
measured from pulmonary residual volume (RV), and
maximal expiratory pressure (PEmax) from total lung
capacity (TLC). The best value of three reproducible
manoeuvres (difference <5%) was included in the analysis.
(Pmax Morgan Medical, Gillingham, Kent, UK). PImax and
PEmax values were assessed both in absolute (cmH2O) and
relative pressure values according to reference values
reported by Morales and colleagues.19
A hand dynamometer (JAMAR dynamometer; Preston,
Jackson, MI, USA) was used to record maximal voluntary
hand grip strength (HGS, in kg) of the finger flexors in both
the dominant and non-dominant hand (HGSd and HGSnd
respectively) during three consecutive manoeuvres sepa-
rated by a 3-minute rest. The maximal value of the
reproducible manoeuvres was used for the analysis. Abso-
lute and relative values were analysed in relation to
reference values.20Statistical analysis
All numerical values are expressed as the mean  SD. As
a case control study the characteristics analysis was con-
ducted using the t test (for quantitative variables of normal
distribution), the KruskaleWallis test (for quantitative
variables of non-normal distribution) or c2 (for qualitative
variables). Normal distribution was tested using a Shapir-
oeWilk test. The variables corresponding to muscle func-
tion and body composition were included in the analyses as
dependent variables. Age and lung function tests were
analysed as independent variables. An unconditioned
multivariate logistic regression model was used to obtain
the association between muscle weakness and exacerba-
tion, after adjusting for potential confounders.21 A p value
of <0.05 was deemed to be significant.
Results
A total of 121 former or currently smoking patients (92%
males) were included in the study. As part of the usual
outpatient treatment, all patients received some inhaled
bronchodilator therapy (formoterol, salmeterol, albuterol,
tiotropium, ipratropium), 5% received oral theophylline,
and 15% received inhaled steroids. No patient received
systemic steroid therapy on a regular basis. At baseline, no
patient presented chronic respiratory failure (defined as
PaO2 <60 mmHg), and none of them qualified for long-term
oxygen therapy. Ten patients, however, showed PaCO2
above 45 mmHg.
General characteristics of the study groups are sum-
marised in Table 1. Seventy-seven patients were at stable
clinical conditions, whereas 44 patients were admitted to
the hospital due to acute exacerbation of COPD. Differ-
ences in body composition were associated with history of
multiple hospital admissions whereas patients under first
hospital admission showed fat and fat-free mass compa-
rable to the stable non admitted COPD group. Collectively,
there were differences between the four groups in some
principal pulmonary function variables. Patients with
history of multiple admissions and present acute exacer-
bation, disclosed greater air trapping (%RV) and lower
diffusing capacity for CO (both TLCO and KCO) compared to
the COPD patients without admissions (p < 0.05 each).
Table 2 shows that muscle weakness was strongly asso-
ciated with the past and current exacerbations of COPD.
Fig. 1 shows a significant decrease of both respiratory and
peripheral muscle strength in all patient groups. After
adjusting by GOLD stage (FEV1), muscle weakness showed
a significant association with two covariates: number of
past admissions and current hospital admission, as indi-
cated in Tables 2e4.
Discussion
The present study confirms that dysfunction of both respi-
ratory and peripheral muscles is highly prevalent in patients
with COPD, even during stable clinical conditions. This is
probably the first report identifying an association between
risk for hospital admission due to exacerbations and base-
line muscle function, irrespective of body weight and BMI.
Table 1 General characteristics of the study population.
Stable COPD Acute exacerbation of COPD
No previous
admissions
With multiple
admissionsa
No previous
admissionsa
With multiple
admissionsa
Patients n (%) 50 (41) 27 (22) 17 (14) 27 (22)
Age Yrs 667 687 678 659
Anthropometrics
Weight Kg 7513 7616 718 7817
BMI kg/m2 274 275 253 285
TBW % 544 573a 573a 554
FM % 289 183b 276 226a
FFM % 203 201 184 226a
Pulmonary function
FEV1 % pred 4917 4215 3716 3713
FVC % pred 7213 6815 6223 5919
TLC % pred 11020 10816 11223 11021
RV % pred 16255 10816 17869 20965b
TLco % pred 6323 5419 6011 4721a
Kco % pred 7521 7226 6320 5825a
PaO2 mmHg 7412 7110 649 6316
PaCO2 mmHg 395 415 4210 436
Smoking exposure
Smoking, % Current/former 34/66 4/96 44/56 33/67
Pack-year 2920 348 4942a 309
Abbreviations: (BMI): body mass index; (TBW): Total body water; (FM); fat mass; (FFM): fat-free mass; (FEV1): forced expiratory volume
in the 1st second; (FVC): forced vital capacity; (TLC) total lung capacity; (RV): residual volume; (Tlco, Kco): transfer capacity for CO.
a p<0.05 ; p values correspond to comparisons with the stable COPD with no previous hospital admission group.
b p<0.01; p values correspond to comparisons with the stable COPD with no previous hospital admission group.
Muscle dysfunction and risk of exacerbation in COPD 1899This association between muscle weakness and risk of
hospitalisation remained significantly increased after
adjustment by the degree of airflow obstruction.
Muscle dysfunction in patients with COPD is not merely
a cosmetic description. Muscle function is relevant from the
clinical point of view as it is associated with increased
symptoms (dyspnoea and discomfort in legs), impaired
physical performance (e.g., decrease in exercise capacity),
reduced health status, and increased risk of mortality,2Table 2 Function of peripheral and respiratory muscles as asse
to both clinical status and history of hospital admissions.
Stable COPD
No previous
admissions
Patients, n (%) 50 (41)
Peripheral muscles
Dominant HGS %pred (%n) 7313 (31)
Non-dominant HGS %pred (%n) 7112 (50)
Expiratory muscles
PEmax %pred 7721
Inspiratory muscles
PImax %pred 8524
Abbreviations: (HGS): hand grip strength, dominant and non-dominan
(Mu¨ller manoeuvre); (PEmax): maximal expiratory pressure measure
percentage of predicted values and in (), the patients incidence of m
a p<0.05; p values correspond to comparisons with the stable COPD
b p<0.01; p values correspond to comparisons with the stable COPD
c p<0.001; p values correspond to comparisons with the stable COPindependent of traditional markers of COPD mortality
such as baseline lung function, age, and cigarette
smoking.6,7 Surprisingly, we identified one study analysing
the potential role of muscle dysfunction as a risk factor of
severe exacerbations of COPD and hospital admissions.11
Our results reported so far suggested a previously
unrecognised association in which muscle dysfunction is not
only present in stable clinical conditions but associated
with the risk of hospital admissions.ssed by maximal voluntary contraction manoeuvres according
Acute exacerbation of COPD
With multiple
admissionsa
First
admissiona
With multiple
admissionsa
27 (22) 17 (14) 27 (22)
6412b (58) 5222c (70) 5818c (68)
6211b (58) 5319b (67) 5518b (82)
8321 5618b 5226b
7118a 5319c 6328b
t; (PImax): Maximal inspiratory pressure measured at the mouth
d at the mouth (Valsalva manoeuvre). Values correspond to the
uscle dysfunction, under 70% of predicted, for each study group.
with no previous hospital admission group.
with no previous hospital admission group.
D with no previous hospital admission group.
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Figure 1 The graph represents the proportion of patients suffering muscle dysfunction determined by a decrease under 70% of
the predicted values. The prevalence of respiratory muscle dysfunction is higher in exacerbated patients but for peripheral
muscles, the prevalence is more notorious in hospital multiple admitted patients.
1900 J. Vilaro´ et al.The present multicentre study offers novel information,
including a particular selection and group assignment of the
patients. We analysed former smokers with COPD who
showed a preserved body weight and were without
comorbidity (known or detected during the clinical assess-
ment processes), regular use of alcohol or sedatives, and
domiciliary oxygen therapy. These selection criteria allow
us to summarise the results in three main concepts, as
follows. The first concept is that patients with stable COPD
without hospital admissions had a high prevalence of
respiratory and peripheral muscle dysfunction as assessed
by strength of inspiratory, expiratory and peripheral
muscles (Table 2). These data confirm previous knowledge
that skeletal muscle dysfunction is among the frequent
extrapulmonary manifestations even in stable COPD.4 The
second concept derived from our study is that, acute
exacerbation of COPD associates with an increase in both
prevalence and severity of global muscle dysfunction (Table
4). It is reasonable to postulate that this additional
impairment in muscle function is associated with the
inflammatory burst and therapy of exacerbations. In fact,Table 3 Crude and adjusted associations between muscle dy
patients without hospital admissions vs. stable patients with mul
Univariate logis
Crude OR (95%
Peripheral muscle weakness
Dominant HGS Lower than 70%pred 5.4 (2.0e14.4)
Non-dominant HGS Lower than 70%pred 2.1 (1.2e8.3)
Expiratory muscle weakness
PEmax Lower than 70%pred 0.88 (0.3e2.5)
Inspiratory muscle weakness
PImax Lower than 70%pred 3.6 (1.4e9.4)
Abbreviations: (HGS): hand grip strength; (PImax): Maximal inspirator
maximal expiratory pressure measured at the mouth (Valsalva manoe
a Adjusted by FEV1.we recently showed that COPD patients who require
admission for exacerbation suffer a global, progressive and
linear deterioration of muscle function.10 The third
concept deals with the evidence that prevalence and
severity of respiratory and peripheral muscle dysfunction
remain elevated even while recovering clinical stability
(Table 3). These data are consistent with the study from
other cohort by Gonzalez et al.,11 who were able to
demonstrate that at hospital discharge, noninvasively
measured respiratory muscle overload were associated with
an increased risk of hospital readmission for exacerbation
in patients with moderate-to-severe COPD. Despite these
information, the ultimate cause of muscle dysfunction has
not yet been determined in either stable or exacerbated
COPD, but our study clearly demonstrates that muscle
weakness strongly associates with the risk for hospital-
isation due to exacerbation, as discussed below.
Exacerbation of COPD represents not only a worsening of
airflow obstruction but also increased respiratory and
systemic demand in a host receiving treatment and with
limited ventilatory reserve.22 With regards to inspiratorysfunction and risk for severe exacerbations in stable COPD
tiple admissions.
tic regression Multivariate logistic regressiona
CI) p Adjusted OR (95% CI) P
<0.001 6.0 (2.0e17.9) <0.001
0.12 1.7 (0.6e4.7) 0.30
0.81 0.6 (0.2e2.2) 0.55
<0.01 3.2 (1.1e9.0) <0.05
y pressure measured at the mouth (Mu¨ller manoeuvre); (PEmax):
uvre).
Table 4 Crude associations between muscle dysfunction and risk for severe exacerbations in stable COPD patients vs. Patients
with acute exacerbation.
Univariate logistic regression Multivariate logistic regressiona
Crude OR (95% CI) p Adjusted OR (95% CI) P
Peripheral muscle weakness
Dominant HGS Lower than 70%pred 2.8 (1.2e6.7) 0.023 2.4 (1.0e6.0) 0.052
Non-dominant HGS Lower than 70%pred 3.1 (1.2e8.3) 0.017 2.6 (1.0e6.9) 0.051
Expiratory muscle weakness
PEmax Lower than 70%pred 7.3 (2.4-21.9) <0.001 6.8 (2.1e21.3) <0.01
Inspiratory muscle weakness
PImax Lower than 70%pred 3.3 (1.5e7.6) 0.004 2.9 (1.2e6.9) <0.05
(HGS): hand grip strength; (PImax): Maximal inspiratory pressure measured at the mouth (Mu¨ller manoeuvre); (PEmax): maximal expiratory
pressure measured at the mouth (Valsalva manoeuvre).
a Adjusted by FEV1.
Muscle dysfunction and risk of exacerbation in COPD 1901muscles, one of the factors related to functional deterio-
ration during exacerbation is the progressive increase in
functional residual capacity due to dynamic air trapping.2
However, our study also demonstrates that the patients
prone to hospitalisation showed a greater dysfunction of
expiratory muscles (assessed as PEmax) and peripheral
muscles (HGS), which cannot be explained by geometrical
changes in the thorax. In addition, systemic inflammation is
associated with reduced muscle strength, exercise toler-
ance, and health status in COPD patients23; exacerbations
have been associated with an inflammatory burst as
assessed by increases in inflammatory mediators in both
sputum and plasma.4
A systemic (global) muscle involvement was captured in
the present study by detecting both peripheral muscle
weakness and modified fat free mass index in patients with
higher risk of exacerbation. Peripheral muscle function
(strength and endurance) is closely related to the absolute
quantity of muscle mass, which is reduced with aging.24e27
Consistent with a previous study,30 however, and intrinsic
to our selection criteria, we were unable to demonstrate
a relationship between age, body weight or BMI, and
susceptibility to multiple exacerbations. Prior retrospective
studies have stated that a significant proportion of patients
with COPD suffer from progressive weight loss in relation to
exacerbation of their disease.28 Other transversal studies in
this field, such as one by Pascual and colleagues,29 have
shown that deterioration of pulmonary function has
a correlation with some anthropometric variables in COPD
patients. We should point out that our patients are from the
Mediterranean area, whereas the study by Vermeeren and
colleagues28 included patients from the north of Europe.
Consequently, we cannot exclude the possibility that there
are differences in the impact of exacerbation of the disease
on patients living in different geographical regions or
having a different ethnic origin.30 Similar differences have
recently been described in cardiovascular disease with
a multifactorial origin.31 In summary, the present study
adds a piece of information demonstrating that peripheral
muscle function may be clinically useful as an additional
marker of risk of exacerbation in patients with COPD,
normal weight, and normal BMI.
One of the limitations of this study is that a cross-
sectional design does not allow us to identify causative
relationships between muscle function and exacerbation ortreatment. Previous studies reported that COPD exacerba-
tion was associated with a progressive loss of water and
muscle body mass that reached minimum values on the day
of hospital discharge.28 Other possible limitations could be
related to the absence of functional assessments of lower
limb muscles such as histological correlates, muscle or fat
tissue biopsies and adipometric techniques. As for the
physical exercise tests or limb muscle measurements,
a practical and ethical limitation has made us restrict
assessments to those that, in our opinion, would not involve
a significant increase in metabolic waste. For similar
reasons, we did not carry out biopsies of muscle or fat.
Finally, we did not perform adipometric assessments or
compartmental anthropometry. This limits us when defining
whether the changes assessed with BIA had a peripheral,
centripetal, or global distribution.
Conclusion
Collectively, the present results extend the concept of
susceptibility to multiple exacerbations of COPD beyond
the pulmonary system to the muscle compartments. We
provide a clinical and epidemiological rationale linking
inspiratory and expiratory muscle dysfunction with
susceptibility to multiple exacerbations of COPD. Our study
shows that muscle function may be clinically useful as
a marker of exacerbation risk in patients with COPD.
These data support the possibility of using respiratory
and peripheral muscle training as an additional treatment
to mitigate the increased susceptibility to exacerbations.
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